using sacituzumab govitecan and other adcs in urothelial cancers
Published 5 years ago • 183 plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
40:12
improving patient outcomes in urothelial carcinoma with novel antibody–drug conjugates
-
1:10
use of sacituzumab govitecan in metastatic urothelial carcinoma
-
31:39
the evolving role of antibody-drug conjugates in the treatment of urothelial carcinoma
-
1:32
antibody-drug conjugates in urothelial carcinoma
-
6:01
sacituzumab govitecan given accelerated fda approval for advanced urothelial cancer
-
0:55
adcs for advanced urothelial carcinoma
-
2:02
sacituzumab govitecan in the treatment of metastatic urothelial carcinoma
-
2:30
the future of antibody-drug conjugates in urothelial cancer
-
1:16
antibody-drug conjugates in advanced urothelial cancer: sacituzumab govitecan
-
1:38
dr. tagawa on sacituzumab govitecan in urothelial carcinoma
-
5:27
sacituzumab govitecan demonstrates metastatic urothelial cancer benefit | yohann loriot
-
1:11
the optimal sequence of adcs and other therapies in advanced and metastatic urothelial cancer
-
3:39
sacituzumab govitecan in previously treated metastatic urothelial carcinoma
-
7:09
understanding antibody drug conjugates
-
3:53
sacituzumab govitecan in metastatic urothelial carcinoma: updates on the phase ii study
-
1:23
recent advances in the use of targeted therapies for metastatic urothelial carcinoma
-
4:21
sacituzumab govitecan plus enfortumab vedotin in advanced urothelial cancer
-
1:18
dr. tagawa on next steps with sacituzumab govitecan in advanced urothelial carcinoma
-
20:21
targeted therapy for the treatment of advanced metastatic urothelial cancer youtube